Fluid biomarkers to predict Alzheimer’s disease: where are we today?

Evidence supporting the use of biomarkers in cerebrospinal fluid (CSF) and plasma continues to accumulate, and these markers may help predict which patients will develop Alzheimer’s disease (AD), an expert panel says.

The panel met in Geneva in 2019 to review recent evidence and provide an up-to-date analysis of the use of fluid biomarkers in AD. The output was presented at AAIC 2020 by Dr Antoine Leuzy of Lund University, Sweden.